- Conditions
- Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- Interventions
- Eplontersen, ALXN2220, Placebo
- Drug · Biological · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 326 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 24
- States / cities
- La Jolla, California • San Francisco, California • Stanford, California + 21 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- Interventions
- ALXN2220
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 35
- States / cities
- Irvine, California • La Jolla, California • Palo Alto, California + 29 more
- Conditions
- Transthyretin Amyloid Cardiomyopathy
- Interventions
- ALXN2220, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1,181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 36
- States / cities
- Irvine, California • La Jolla, California • Palo Alto, California + 30 more